Subscribe Sign In

Why register?

Home
News
Events
- Find an event
- Live event coverage
Deep Dive
Sales and marketing
Digital
Market Access
Oncology
Patients
R&D
Spotlight On
- Frontiers Health 2021
- The Future of Generics
Advertise

Search

Search

Close

Trending

Bayer bails on $670m CAR-T partnership with Atara

Sidekick and Pfizer prep launch of DTx for atopic dermatitis

Coalition aims to improve cancer drug access in poorer nations

Conducting successful commercial research in a primary care setting

EU imposes Horizon funding block on UK scientists

favezelimab

BMS_sign

News/ News/ Oncology

BMS gets FDA OK for first LAG-3 checkpoint inhibitor

Phil Taylor Bristol-Myers Squibb, favezelimab, LAG-3, Merck & Co, Opdivo, Opdualag, regulatory approval, relatlimab 0 Comment

Bristol-Myers Squibb has won FDA approval for the first LAG-3 inhibitor drug ahead of its rivals in cancer

X

BMS gets FDA OK for first LAG-3 checkpoint inhibitor

https://pharmaphorum.com/news/bms-gets-fda-ok-for-first-lag-3-checkpoint-inhibitor/

Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox

Featured content

How to improve payer engagement with tailored value communication

How to improve payer engagement with tailored value communication

How will NICE fare in a post-Brexit world?

How will NICE fare in a post-Brexit world?

Events

MAPS 2018 EMEA Annual Meeting

MAPS 2018 EMEA Annual Meeting

Cell & Gene Therapy 2018

Cell & Gene Therapy 2018

Patient Engagement Event - a real world snapshot, beyond the talk

Patient Engagement Event - a real world snapshot, beyond the talk

Most popular

Most Viewed

Moderna's HIV vaccine prepped for trials in Africa
Large UK study suggests vaccination helps treat long COVID
Bayer bails on $670m CAR-T partnership with Atara
Sidekick and Pfizer prep launch of DTx for atopic dermatitis
Pharma bad boy Martin Shkreli is on the streets again

Tweets from @pharmaphorum

Tweets by @pharmaphorum

Advertise
pharmaphorum connect

Contribute
Work for pharmaphorum

About us
Contact us
Privacy policy
Terms & conditions
Cookie Policy

The rights of trade mark owners are acknowledged. pharmaphorum media limited

Website and content copyright © 2009-, pharmaphorum media limited or its licensors; all rights reserved.

© 2022

Powered by WordPress • Themify WordPress Themes

Login

Username or Email Address

Password

Remember Me

Lost your password?

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com